ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1350

Sustained Improvement in Physical Function, Disease Impact and Health­-Related Quality of Life in Patients with Psoriatic Arthritis Treated with Bimekizumab: 3-Year Results from a Phase 2b Open-Label Extension Study

Laure Gossec1, Akihiko Asahina2, Alice Gottlieb3, Laura Coates4, Barbara Ink5, Deepak Assudani6, Jason Coarse7, Scarlett Hellot8, Jason Eells6 and Philip Mease9, 1Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, 2Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan, 3Icahn School of Medicine at Mount Sinai, New York, NY, 4Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 5UCB Celltech, Slough, UK, Slough, United Kingdom, 6UCB Pharma, Slough, United Kingdom, 7UCB Pharma, Raleigh, NC, 8UCB Pharma, Colombes, France, 9Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA

Meeting: ACR Convergence 2021

Keywords: Biologicals, clinical trial, Disease Activity, Patient reported outcomes, Psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 8, 2021

Session Title: Spondyloarthritis Including PsA – Treatment Poster II: Psoriatic Arthritis I (1329–1363)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits both interleukin (IL)-17F and IL-17A, and has demonstrated clinical improvements in joint and skin outcomes up to 152 weeks (wks) with an acceptable safety profile in patients (pts) with active psoriatic arthritis (PsA).1,2 Achievement of low disease activity in pts with PsA has been associated with improvements in pt-reported health-related quality of life (HRQoL).3 To report long-term impact of BKZ treatment, up to 3 years, on pt-reported outcome (PRO) measures from a phase 2b dose-ranging study (BE ACTIVE; NCT02969525) and its open-label extension (OLE; NCT03347110).

Methods: BE ACTIVE and OLE study designs have been described previously.1,2 Pts who completed 48 wks of BKZ treatment without meeting withdrawal criteria were eligible for OLE entry. All OLE pts received BKZ 160 mg every 4 wks. Data are presented from BE ACTIVE baseline (BL) and at Wks 48 and 152. PROs reported (full analysis set [FAS]): 9-­item Psoriatic Arthritis Impact of Disease (PsAID-9) individual domains (change from BL [CfB]) and Patient Acceptable Symptom State (PASS [score≤4]),4 Health Assessment Questionnaire Disability Index (HAQ-DI) Minimal Clinically Important Difference (MCID; ≥0.35 decrease from BL), CfB in Short Form-36 (SF-36) individual domains, CfB in SF-36 Physical and Mental Component Summaries (PCS/MCS), and CfB in Patient’s Assessment of Arthritis Pain (PtAAP) visual analogue scale (VAS). In addition to observed case (OC) data, we report results with non-responder imputation (NRI) or multiple imputation (MI; based on the missing at random assumption).

Results: Of 206 randomized pts at BL in BE ACTIVE, 66.5% had psoriasis body surface area ≥3%, 18.9% had prior tumor necrosis factor inhibitor exposure, and 63.6% received concomitant methotrexate. Mean BL PRO scores were comparable across dose groups in BE ACTIVE (Table 1). At Wks 48/152, the proportions of patients who achieved PsAID-9 PASS (NRI) were 74.2–76.8%/63.7–67.1%; the proportions of patients who achieved HAQ-DI MCID (NRI) were 47.6–53.7%/42.7–45.1% (Figure 1A–D). All PsAID-9 domains and the majority of the 8 SF-36 domains improved from BL to Wks 48 and 152, including measures of fatigue and bodily pain. SF-36 PCS improved from BL to Wks 48 and 152 and SF-36 MCS remained within the normal range from BL, as expected (Figure 1E–F; Table 2). Pts showed sustained improvements in pain by mean CfB in PtAAP VAS score at Wk 48 (between −26.8 and −34.7; MI) and Wk 152 (between −31.3 and −33.0; MI) (Figure 1G). There were no clear differences between pts who completed either BKZ 160 mg or BKZ 320 mg in BE ACTIVE prior to receiving BKZ 160 mg in the OLE.

Conclusion: BKZ treatment is associated with sustained improvements in PRO measures of disease impact up to 3 years, including in pain and fatigue. Furthermore, BKZ treatment is associated with substantial and durable improvements in measures of overall physical function and HRQoL up to 3 years.

References: 1. Ritchlin CT. Lancet 2020;395:427–40; 2. McInnes IB. Ann Rheum Dis 2020;79:1153–4; 3. Gossec L. Ann Rheum Dis 2020;79:1687; 4. Gossec L. Ann Rheum Dis 2014;73:1012–9.

Full analysis set. All patients received BKZ 160 mg during the OLE (Wks 48–152) after completing BKZ 160 mg or 320 mg in BE ACTIVE: [a] Includes pts within the indicated analysis set from the dose-response, double-blind period who were subsequently re-randomized to 160 mg, or [b] pts who received 320 mg during the dose-blind periods; all pts received 160 mg during the open-label extension. Lower HAQ-DI scores correspond to better performance of daily activities; Higher SF_36 scores indicate better pt HRQoL; Lower PsAID-9 scores correspond to lower impact of disease on pt QoL; Lower PtAAP VAS scores indicate less pain. BKZ: bimekizumab; BSA: body surface area; HAQ­-DI: Health Assessment Questionnaire Disability Index; hs-CRP: high sensitivity C-reactive protein; MTX: methotrexate; OLE: open-label extension; PASS: Patient Acceptable Symptom State; PRO: patient-reported outcome; PsAID­-9: Psoriatic Arthritis Impact of Disease-9; PtAAP: Patient’s Assessment of Arthritis Pain; pts: patients; (HR)QoL: (health-related) quality of life; SD: standard deviation; SF_36 MCS: Short Form_36 Mental Component Summary; SF_36 PCS: Short Form_36 Physical Component Summary; SJC: swollen joint count; TJC: tender joint count; TNF: tumor necrosis factor; VAS: visual analogue scale; wk: week.

Full analysis set. All patients received BKZ 160 mg during the OLE (Wks 48–152) after completing BKZ 160 mg or 320 mg in BE ACTIVE: [a] Includes pts within the indicated analysis set from the dose-response, double-blind period who were subsequently re-randomized to 160 mg, or [b] pts who received 320 mg during the dose-blind periods; all pts received 160 mg during the open-label extension. Higher SF_36 scores indicate better pt HRQoL; Lower PsAID-9 scores correspond to lower impact of disease on pt QoL. Missing data were imputed using multiple imputation based on the Markov-Chain Monte Carlo method for the intermittent missing data, followed by monotone regression for the monotone missing data assuming missing at random. BKZ: bimekizumab; BL: baseline; CfB: change from Baseline; OLE: open-label extension; PsAID­-9: Psoriatic Arthritis Impact of Disease-9; pts: patients; (HR)QoL: (health-related) quality of life; SE: standard error; SF_36: Short Form_36; wk: week.

Full analysis set. All patients received BKZ 160 mg during the OLE (Wks 48–152) after completing BKZ 160 mg or 320 mg in BE ACTIVE: [a] Includes pts within the indicated analysis set from the dose-response, double-blind period who were subsequently re-randomized to 160 mg, or [b] pts who received 320 mg during the dose-blind periods; all pts received 160 mg during the open-label extension; [c] OC baseline [160 mg/320 mg/Total]: n=124/82/206, respectively; Wk 48 [160 mg/320 mg/Total]: n=115/76/191, respectively; Wk 152 [160 mg/320 mg/Total]: n=95/62/157, respectively; [d] OC Wk 48 [160 mg/320 mg/Total]: n=115/76/191, respectively; Wk 152 [160 mg/320 mg/Total]: n=95/62/157, respectively. Higher SF_36 scores indicate better pt HRQoL; Lower PtAAP VAS scores indicate less pain. BKZ: bimekizumab; HAQ­-DI: Health Assessment Questionnaire Disability Index; MCID: minimal clinically important difference; MI: multiple imputation; NRI: non-responder imputation; OC: observed case; OLE: open-label extension; PASS: Patient Acceptable Symptom State; PsAID­-9: Psoriatic Arthritis Impact of Disease-­9; PtAAP: Patient’s Assessment of Arthritis Pain; pts: patients; (HR)QoL: (health-related) quality of life; SF_36 MCS: Short Form_36 Mental Component Summary; SF_36 PCS: Short Form_36 Physical Component Summary; VAS: visual analogue scale; wk: week.


Disclosures: L. Gossec, Galapagos, 5, Sandoz, 5, Sanofi, 5, AbbVie, 2, Amgen, 2, 5, Bristol Myers Squibb, 2, Biogen, 2, Celgene, 2, Eli Lilly, 2, 5, Gilead, 2, Janssen, 2, 5, Novartis, 2, Pfizer, 2, 5, Samsung Bioepis, 2, Sanofi-Aventis, 2, UCB, 2; A. Asahina, AbbVie, 5, 6, Celgene, 5, 6, Eisai, 5, 6, Eli Lilly, 5, 6, Janssen, 5, 6, Kyowa Kirin, 5, 6, Leo Pharma, 5, 6, Maruho, 5, 6, Mitsubishi Pharma, 5, 6, Sun Pharma, 5, 6, Taiho Pharma, 5, 6, Torii Pharmaceutical, 5, 6, UCB Pharma, 5, 6; A. Gottlieb, Boehringer Ingelheim, 1, 2, 5, Incyte, 1, 2, 5, Janssen, 1, 2, 5, Novartis, 1, 2, 5, UCB, 1, 2, 5, Xbiotech, 1, 2, 5, Bristol Myers Squibb, 1, 2, LEO Pharma, 1, 2, AnaptysBio, 1, 2, Avotres, 1, 2, Eli Lilly, 1, 2, Pfizer, 1, 2, Beiersdorf, 1, 2, Sun Pharmaceuticals, 1, 2, 5, Dermavant, 1, 2, GlaxoSmithKline, 1, 2; L. Coates, Abbvie, 5, 6, Amgen, 5, 6, Biogen, 6, Celgene, 5, 6, Gilead, 6, Janssen, 6, Eli Lilly, 5, 6, Medac, 6, Novartis, 5, 6, Pfizer, 5, 6, UCB Pharma, 6, Galapagos, 6, GSK, 6, Boehringer Ingelheim, 6, Domain, 2; B. Ink, GSK, 11, UCB Pharma, 3, 11; D. Assudani, UCB Pharma, 3; J. Coarse, UCB Pharma, 3; S. Hellot, UCB Pharma, 3; J. Eells, UCB Pharma, 3, 11; P. Mease, AbbVie, 2, 5, 6, Amgen, 2, 5, 6, Bristol-Myers Squibb, 2, 5, Eli Lilly, 2, 5, 6, Galapagos, 2, 5, Celgene, 2, Boehringer Ingelheim, 2, Genentech, 2, 5, 6, Janssen, 2, 5, 6, Gilead Sciences, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, Sun Pharma, 2, 5, UCB Pharma, 2, 6, GSK, 2.

To cite this abstract in AMA style:

Gossec L, Asahina A, Gottlieb A, Coates L, Ink B, Assudani D, Coarse J, Hellot S, Eells J, Mease P. Sustained Improvement in Physical Function, Disease Impact and Health­-Related Quality of Life in Patients with Psoriatic Arthritis Treated with Bimekizumab: 3-Year Results from a Phase 2b Open-Label Extension Study [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/sustained-improvement-in-physical-function-disease-impact-and-health-related-quality-of-life-in-patients-with-psoriatic-arthritis-treated-with-bimekizumab-3-year-results-from-a-phase-2b-open-l/. Accessed February 6, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sustained-improvement-in-physical-function-disease-impact-and-health-related-quality-of-life-in-patients-with-psoriatic-arthritis-treated-with-bimekizumab-3-year-results-from-a-phase-2b-open-l/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences